Yahoo
NasdaqCM USD

SciSparc Ltd. (SPRC)

5.62 -0.05 (-0.88%)
As of 9:41:32 AM EDT. Market Open.
Chart Range Bar
Loading chart for SPRC
  • Previous Close 5.67
  • Open 5.80
  • Bid 4.03 x 200
  • Ask 7.28 x 200
  • Day's Range 5.41 - 5.80
  • 52 Week Range 2.98 - 80.10
  • Volume 41,532
  • Avg. Volume 333,339
  • Market Cap (intraday) 129.672M
  • Beta (5Y Monthly) 2.45
  • PE Ratio (TTM) 0.06
  • EPS (TTM) 98.07
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and palmitoylethanolamide oral tablets CannAmide in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

scisparc.com

3

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 9/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

SPRC
54.08%
S&P 500 (^GSPC)
12.12%

1-Year Return

SPRC
74.41%
S&P 500 (^GSPC)
19.63%

3-Year Return

SPRC
99.26%
S&P 500 (^GSPC)
69.96%

5-Year Return

SPRC
99.98%
S&P 500 (^GSPC)
69.16%

Statistics

View More

Valuation Measures

Annual
As of 9/1/2026
  • Market Cap

    3.29M

  • Enterprise Value

    -930.88k

  • Trailing P/E

    0.06

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.82

  • Price/Book (mrq)

    0.78

  • Enterprise Value/Revenue

    174.58

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -60.68%

  • Return on Equity (ttm)

    -178.39%

  • Revenue (ttm)

    856k

  • Net Income Avi to Common (ttm)

    -12.18M

  • Diluted EPS (ttm)

    98.07

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    4.59M

  • Total Debt/Equity (mrq)

    7.11%

  • Levered Free Cash Flow (ttm)

    833k

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

5.62 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: